Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nedosiran→

Nedosiran Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2266591-83-5
Molecular formula
C662H865F19N231O413P57S6
Molecular weight
20985.24 g/mol
Drug class
Lactate dehydrogenase A (LDHA)-directed small interfering RNA (siRNA)RNA interference therapy
Mechanism of action
A GalNAc-conjugated siRNA is taken up by hepatocytes and directs RNA-induced silencing complex-mediated degradation of LDHA mRNA, reducing hepatic glycolate-to-glyoxylate conversion and lowering oxalate production.
Indications / reported uses
  • Reduction of urinary oxalate in adults and children aged 2 years and older with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function (eGFR at least 30 mL/min/1.73 m²) under the US RIVFLOZA indication

Sources: NLM DailyMed — RIVFLOZA (nedosiran), updated 3 March 2025 · FDA Orphan Drug database — Nedosiran approved age expansion · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nedosiran Environmental Risk Assessment (ERA) (the Nedosiran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.